Keen Mind contains a unique extract of Bacopa (Bacopa monnieri) - CDRI 08 – that is the result of 30 years of meticulous research and development by the Indian government’s Central Drug Research Institute (CDRI) and is further supported by Australian clinical trials.
KeenMind aids memory and recall, helps with concentration and attention span. It can also aid mental clarity and learning retention. Clinical trials have demonstrated that KeenMind:
- Enhances retention of new information
- Improves learning rate and memory
- Has the potential to assist with learning in children
- Many people may benefit from taking KeenMind, including:
- Children and students, to facilitate learning and concentration
- Mature and elderly individuals, to aid memory and mental performance
- Those with intellectually demanding jobs or needing to constantly take in high volumes of information, to support memory retention and recall
- People who are under pressure, where improved ability to focus would be beneficial
The first double blind placebo-controlled trial for KeenMind was published in 2001. This study was conducted in Australia by Professor Con Stough and colleagues at Swinburne University to investigate the memory enhancing effects in 46 healthy subjects aged between 18 and 60 years.
Results showed significantly improved speed of visual information processing, learning rate and memory consolidation, and decreased anxiety; maximal effects were evident after 12 weeks. Roodenrys and colleagues replicated the memory enhancing effects of KeenMind in 76 participants aged between 40 and 65 years. They reported a significant decrease in the rate of forgetting newly acquired information after 90 days of treatment in a sample of older individuals than previously used by Stough and colleagues (2001).
The most recent study on KeenMind was published in the Journal of Phytotherapy in August 2008. This study of 62 healthy participants was conducted at the Brain Sciences Institute at Swinburne University in Melbourne Australia. Cognitive function tests commonly used in dementia trials (Cognitive Drug Research (CDR) computerised assessment system) were used to assess the effects of KeenMind compared to a placebo, in a randomised double-blind, placebo-controlled trial (the gold standard in clinical research).
After 90 days of treatment with 2 capsules of KeenMind the participants had significantly improved performance on “working memory” (the ability to hold information “online” in the brain and actually do something with that information) and “visual information processing” (a measure of the ability to sustain attention). Slowed information processing is one of the most prominent cognitive deficits in the elderly.
In the studies conducted it appears that the cognitive effects of KeenMind are achieved with no clinically relevant side effects, even in children and elderly participants.
The capsules are best taken with breakfast. Adults take 2 capsules daily and children can take one capsule daily (or as directed by a health care professional).
The formulation of KeenMind is the Bacopa extract which has been extensively investigated by the Indian
government’s Central Drug Research Institute (CDRI).
Phytochemical analysis of this plant was first conducted at the CDRI in 1963 and 1965. As with most herbal medicines, a complex mix of constituents is needed for their therapeutic action, as was evidenced in the case of Bacopa. Many active constituents were identified including alkaloids, saponins, D-mannitol, betulic acid, ß-sitosterol and stigmasterols, and the steroidal saponins, specifically Bacosides A and B which are believed to be essential for the clinical efficacy of this herb.
The CDRI developed the unique standardised extract of Bacopa monnieri KeenMind (CDRI 08). This broad-spectrum extract has a unique profile of constituents. While Bacopa has been reported to have many actions, it is the memory enhancing effects which have attracted most attention and pharmacological studies have supported these anecdotal claims for Bacopa.